Skip To Content

News & Events

Given the activity level of our attorneys, we are confident in showcasing the various matters that our clients have given us the privilege to work on and approved to post here.

Posts

  • November 29 2016

    Bellerophon Therapeutics Inc. announced the closing of their Registered Direct offering in the amount of $12,000.000.  EG&S acted as counsel to the Placement Agent.

  • November 29 2016

    Cellectar Biosciences, Inc. announced the closing of their Underwritten offering in the amount of $9,200,000.  EG&S acted as counsel to the Underwriter.

  • November 29 2016

    Rosetta Genomics Ltd. announced the closing of their PIPE offering in the amount of $3,707,500.  EG&S acted as counsel to the Investor.

  • November 23 2016

    Client Alert: Federal Judge Blocks Implementation

    As we previously advised, on May 18, 2016, the U.S. Department of Labor published the final rule updating the overtime regulations.  Click here to read the full alert.

  • November 23 2016

    MotifBio PLC announced the closing of their Underwritten offering in the amount of $17,020,667.  EG&S acted as counsel to the Underwriter.

  • November 21 2016

    MagneGas Corporation announced the closing of their Shelf offering in the amount of $3,000,000.  EG&S acted as counsel to the Investor.

  • November 09 2016

    Bridgeline Digital Inc. announced the closing of their PIPE offering in the amount of $1,091,901.  EG&S acted as counsel to the Placement Agent.

  • November 03 2016

    Sunshine Heart, Inc. announced the closing of their Registered Direct offering in the amount of $3,600,000.  EG&S acted as counsel to the Placement Agent.

“It’s with genuine appreciation to all of our clients that we are in a position to achieve and maintain our leadership position in so many areas.”